Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$331M Sell
1,316,850
-3,400
-0.3% -$731K 0.66% 23
2026
Q1
$287M Buy
1,320,250
+150,645
+13% +$33.4M 0.69% 18
2025
Q4
$267M Sell
1,169,605
-38,000
-3% -$8.66M 0.62% 18
2025
Q3
$280M Sell
1,207,605
-111,056
-8% -$22.6M 0.7% 19
2025
Q2
$245M Buy
1,318,661
+11,582
+0.9% +$2.15M 0.61% 23
2025
Q1
$274M Buy
1,307,079
+221,317
+20% +$43M 0.84% 18
2024
Q4
$193M Sell
1,085,762
-75,068
-6% -$13.8M 0.58% 23
2024
Q3
$229M Buy
1,160,830
+69,271
+6% +$12.9M 0.76% 19
2024
Q2
$187M Sell
1,091,559
-93,441
-8% -$15.5M 0.69% 22
2024
Q1
$216M Buy
+1,185,000
New +$204M 0.68% 23

Other funds holding ABBV

Danske Bank's ABBV Position: Q2 2026 in Review

Danske Bank reduced its AbbVie (ABBV) stake by 0.26% in Q2 2026, selling an estimated $731K and leaving 1,316,850 shares worth $331M. The position accounts for 0.66% of the portfolio, ranked #23.

Danske Bank first reported a position in ABBV in Q1 2024 and has held it in 10 quarters since. 4,187 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Danske Bank held 1,316,850 shares of AbbVie worth $331M as of Q2 2026.
  • Danske Bank sold 3,400 AbbVie shares in Q2 2026, an estimated $731K.
  • AbbVie made up 0.66% of Danske Bank's portfolio in Q2 2026, its #23 holding.
  • Danske Bank first reported a position in AbbVie in Q1 2024 and has held it in 10 quarters since.
  • 4,187 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.